U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Hormone Receptor-Positive Breast Carcinoma

MedGen UID:
1650178
•Concept ID:
C4745241
•
Neoplastic Process
Synonyms: Refractory Hormone Receptor Positive Breast Adenocarcinoma; Refractory Hormone Receptor Positive Breast Carcinoma

Definition

Hormone receptor-positive breast adenocarcinoma that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Hormone Receptor-Positive Breast Carcinoma

Professional guidelines

PubMed

Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Jhaveri K, Marmé F
Cancer Treat Rev 2024 Feb;123:102670. Epub 2023 Dec 9 doi: 10.1016/j.ctrv.2023.102670. PMID: 38211404
An evaluation of fulvestrant for the treatment of metastatic breast cancer.
Soleja M, Raj GV, Unni N
Expert Opin Pharmacother 2019 Oct;20(15):1819-1829. Epub 2019 Sep 5 doi: 10.1080/14656566.2019.1651293. PMID: 31486688
Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Hecht KA, Selby C
Ann Pharmacother 2019 Feb;53(2):195-203. Epub 2018 Aug 6 doi: 10.1177/1060028018793656. PMID: 30079740

Recent clinical studies

Etiology

Racial and Ethnic Disparity in Preoperative Chemosensitivity and Survival in Patients With Early-Stage Breast Cancer.
Roy AM, Patel A, Catalfamo K, Attwood K, Khoury T, Yao S, Gandhi S
JAMA Netw Open 2023 Nov 1;6(11):e2344517. doi: 10.1001/jamanetworkopen.2023.44517. PMID: 37991763Free PMC Article
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR(+)/HER2(-) Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).
Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Rugo HS, Purkayastha D, Moulder S
Clin Cancer Res 2021 Aug 1;27(15):4177-4185. Epub 2021 Mar 15 doi: 10.1158/1078-0432.CCR-20-2114. PMID: 33722897Free PMC Article
Everolimus.
Hasskarl J
Recent Results Cancer Res 2018;211:101-123. doi: 10.1007/978-3-319-91442-8_8. PMID: 30069763
Lapatinib.
Voigtlaender M, Schneider-Merck T, Trepel M
Recent Results Cancer Res 2018;211:19-44. doi: 10.1007/978-3-319-91442-8_2. PMID: 30069757
Breast cancer in men.
Giordano SH, Buzdar AU, Hortobagyi GN
Ann Intern Med 2002 Oct 15;137(8):678-87. doi: 10.7326/0003-4819-137-8-200210150-00013. PMID: 12379069

Diagnosis

Sequencing systemic therapy in hormone-receptor positive metastatic breast cancer: a modern paradigm.
Haddad SA, Dizon DS, Graff SL
Chin Clin Oncol 2023 Aug;12(4):42. Epub 2023 Aug 10 doi: 10.21037/cco-23-22. PMID: 37574571
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
Dubash TD, Bardia A, Chirn B, Reeves BA, LiCausi JA, Burr R, Wittner BS, Rai S, Patel H, Bihani T, Arlt H, Bidard FC, Kaklamani VG, Aftimos P, Cortés J, Scartoni S, Fiascarelli A, Binaschi M, Habboubi N, Iafrate AJ, Toner M, Haber DA, Maheswaran S
Breast Cancer Res Treat 2023 Aug;201(1):43-56. Epub 2023 Jun 15 doi: 10.1007/s10549-023-06998-w. PMID: 37318638Free PMC Article
Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?
Borges VF
J Clin Oncol 2021 Dec 10;39(35):3890-3896. Epub 2021 Oct 28 doi: 10.1200/JCO.21.01910. PMID: 34709849
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN, Cristofanilli M
Curr Treat Options Oncol 2017 Jan;18(1):6. doi: 10.1007/s11864-017-0443-7. PMID: 28197838
Breast cancer in men.
Giordano SH, Buzdar AU, Hortobagyi GN
Ann Intern Med 2002 Oct 15;137(8):678-87. doi: 10.7326/0003-4819-137-8-200210150-00013. PMID: 12379069

Therapy

Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Jhaveri K, Marmé F
Cancer Treat Rev 2024 Feb;123:102670. Epub 2023 Dec 9 doi: 10.1016/j.ctrv.2023.102670. PMID: 38211404
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.
Guerrero-Zotano Á, Belli S, Zielinski C, Gil-Gil M, Fernandez-Serra A, Ruiz-Borrego M, Ciruelos Gil EM, Pascual J, Muñoz-Mateu M, Bermejo B, Margeli Vila M, Antón A, Murillo L, Nissenbaum B, Liu Y, Herranz J, Fernández-García D, Caballero R, López-Guerrero JA, Bianco R, Formisano L, Turner N, Martín M
Clin Cancer Res 2023 Apr 14;29(8):1557-1568. doi: 10.1158/1078-0432.CCR-22-2206. PMID: 36749874Free PMC Article
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P
Lancet Oncol 2019 Aug;20(8):1124-1135. Epub 2019 Jun 27 doi: 10.1016/S1470-2045(19)30328-6. PMID: 31257177
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR(+)/HER2(-) Metastatic Breast Cancer.
Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J
Clin Cancer Res 2017 Sep 1;23(17):5218-5224. Epub 2017 May 22 doi: 10.1158/1078-0432.CCR-17-0754. PMID: 28533223Free PMC Article
Breast Cancer: Current Molecular Therapeutic Targets and New Players.
Nagini S
Anticancer Agents Med Chem 2017;17(2):152-163. doi: 10.2174/1871520616666160502122724. PMID: 27137076

Prognosis

Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
Dubash TD, Bardia A, Chirn B, Reeves BA, LiCausi JA, Burr R, Wittner BS, Rai S, Patel H, Bihani T, Arlt H, Bidard FC, Kaklamani VG, Aftimos P, Cortés J, Scartoni S, Fiascarelli A, Binaschi M, Habboubi N, Iafrate AJ, Toner M, Haber DA, Maheswaran S
Breast Cancer Res Treat 2023 Aug;201(1):43-56. Epub 2023 Jun 15 doi: 10.1007/s10549-023-06998-w. PMID: 37318638Free PMC Article
Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?
Borges VF
J Clin Oncol 2021 Dec 10;39(35):3890-3896. Epub 2021 Oct 28 doi: 10.1200/JCO.21.01910. PMID: 34709849
Lapatinib.
Voigtlaender M, Schneider-Merck T, Trepel M
Recent Results Cancer Res 2018;211:19-44. doi: 10.1007/978-3-319-91442-8_2. PMID: 30069757
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR(+)/HER2(-) Metastatic Breast Cancer.
Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J
Clin Cancer Res 2017 Sep 1;23(17):5218-5224. Epub 2017 May 22 doi: 10.1158/1078-0432.CCR-17-0754. PMID: 28533223Free PMC Article
Breast Cancer: Current Molecular Therapeutic Targets and New Players.
Nagini S
Anticancer Agents Med Chem 2017;17(2):152-163. doi: 10.2174/1871520616666160502122724. PMID: 27137076

Clinical prediction guides

A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.
Cescon DW, Hilton J, Morales Murilo S, Layman RM, Pluard T, Yeo B, Park IH, Provencher L, Kim SB, Im YH, Wyce A, Krishnatry AS, Hicks K, Zhang Q, Barbash O, Khaled A, Horner T, Dhar A, Oliveira M, Sparano JA
Clin Cancer Res 2024 Jan 17;30(2):334-343. doi: 10.1158/1078-0432.CCR-23-0133. PMID: 37992310Free PMC Article
Cell facilitation promotes growth and survival under drug pressure in breast cancer.
Emond R, Griffiths JI, Grolmusz VK, Nath A, Chen J, Medina EF, Sousa RS, Synold T, Adler FR, Bild AH
Nat Commun 2023 Jun 29;14(1):3851. doi: 10.1038/s41467-023-39242-6. PMID: 37386030Free PMC Article
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR(+)/HER2(-) Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).
Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Rugo HS, Purkayastha D, Moulder S
Clin Cancer Res 2021 Aug 1;27(15):4177-4185. Epub 2021 Mar 15 doi: 10.1158/1078-0432.CCR-20-2114. PMID: 33722897Free PMC Article
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P
Lancet Oncol 2019 Aug;20(8):1124-1135. Epub 2019 Jun 27 doi: 10.1016/S1470-2045(19)30328-6. PMID: 31257177
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN, Cristofanilli M
Curr Treat Options Oncol 2017 Jan;18(1):6. doi: 10.1007/s11864-017-0443-7. PMID: 28197838

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...